Related Experiment Video

Updated: Jun 12, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

[Synergistic effect of deficiency in thrombosis-related genes]

Yue-chun Shen1, Bi-hui Luo, Bi-ru Ou

  • 1Department of Cardiology, First Affiliated Hospital, Guangzhou Medical College, Guangzhou, Guangdong, 510120 PR China.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics
|June 10, 2010
PubMed
Abstract

Insights

Combined deficiency in alpha-galactosidase A (Gla) and factor V Leiden (Fvl) genes in mice led to significantly increased fibrin deposition and thrombus formation. This suggests a synergistic effect between Gla and Fvl deficiencies in thrombosis.

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Context:

  • Thrombosis is a significant health concern, often influenced by genetic factors.
  • Understanding gene interactions in thrombosis is crucial for identifying disease mechanisms.
  • Deficiencies in specific genes, such as alpha-galactosidase A (Gla) and factor V Leiden (Fvl), are implicated in thrombotic events.

Purpose:

  • To investigate the synergistic interaction between alpha-galactosidase A (Gla) deficiency and factor V Leiden (Fvl) mutation in a mouse model.
  • To analyze the impact of combined Gla and Fvl gene deficiencies on thrombosis-related phenotypes, including fibrin deposition and thrombus formation.

Summary:

  • Mice with combined Gla and Fvl gene deficiencies exhibited significantly increased fibrin deposition in organs compared to single-mutation carriers.
  • A notable increase in the number of thrombi was observed in mice with both Gla and Fvl deficiencies.
  • These findings demonstrate a synergistic effect of Gla and Fvl deficiencies on thrombosis in a murine model.

Impact:

  • The study highlights a potential synergistic interaction between GLA deficiency and FVL or other thrombosis-related gene defects.
  • These findings suggest a possible genetic basis for severe early-onset thrombosis in patients with combined genetic deficiencies.
  • This research provides insights into the complex genetic landscape of thrombosis and may inform future diagnostic and therapeutic strategies.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells18:30

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.